April 2026

PhD with a minimum of 55% in post-graduation (M.Sc / M. Pharm / M.Tech. degree in Biotechnology or allied discipline), Experience in Immunology, Cancer model, cell culture etc., Strong expertise and publication in the domain of immunology and cancer biology, Experience in pharmaco-immunology and preclinical models. 

Post Graduate Degree, including the integrated PG degrees, with five years’ post qualification experience or PhD + two years post qualification experience.

M.Sc. in Marine Science / Marine Biology / Marine Biotechnology / Oceanography / Oceanography and Coastal Area Studies / Biotechnology / Microbiology / Botany / Plant Biology / Plant Biotechnology/ Biochemistry from a recognized university

Experience in QC Planning, Trackwise, AMV, Review, OOS, OOT, QMS, LIMS, CAPA, QMS and Risk Assessment QC Analyst (Micro)

Strong understanding of regulatory guidelines and documentation practices. Detail-oriented with excellent analytical and communication skills.

Lupin Limited announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg.

Amgen announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease

Masters / Integrated Masters in Chemistry (preferably Inorganic/Organic Chemistry/ Pharmaceutical/Medicinal Chemistry/Materials/Polymer)

MS Pharm (Pharmacology & Toxicology/Regulatory Toxicology/ Biotechnology)/ MPharm/ MTech (Biotechnology/ Bioscience/ Bioengineering)/ MD (Pharmacology/ Pharmacology & Toxicology).

M.Sc. in Biochemistry/ Microbiology/Biotechnology/Life Sciences from a recognised University or equivalent